-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OcJeBaKAsP9qzjuTPimwBlHX1O9Ri/7MTGcAAtEhKTuU6MS1GSQRpYpLETxHhKLb k/w1ZkPCVqqkY3//DZJ4Sw== 0000946486-04-000055.txt : 20040813 0000946486-04-000055.hdr.sgml : 20040813 20040813154837 ACCESSION NUMBER: 0000946486-04-000055 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040812 FILED AS OF DATE: 20040813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZODDA DENI M PHD CENTRAL INDEX KEY: 0001139219 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26422 FILM NUMBER: 04974279 BUSINESS ADDRESS: STREET 1: 350 SOUTH MAIN STREET STREET 2: SUITE 307 CITY: DOYELSTOWN STATE: PA ZIP: 18901 MAIL ADDRESS: STREET 1: 350 SOUTH MAIN STREET STREET 2: SUITE 307 CITY: DOYELSTOWN STATE: PA ZIP: 18901-4874 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DISCOVERY LABORATORIES INC /DE/ CENTRAL INDEX KEY: 0000946486 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171943 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 350 MAIN STREET SUITE 307 CITY: DOYLESTOWN STATE: PA ZIP: 18901 BUSINESS PHONE: 2152404699 MAIL ADDRESS: STREET 1: 350 MAIN STREET SUITE 307 CITY: DOYLESTOWN STATE: PA ZIP: 18901 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 19961121 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN INC DATE OF NAME CHANGE: 19950609 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2004-08-12 0 0000946486 DISCOVERY LABORATORIES INC /DE/ DSCO 0001139219 ZODDA DENI M PHD 350 SOUTH MAIN STREET SUITE 307 DOYELSTOWN PA 18901-4874 0 1 0 0 Sr VP, Business Development Common Stock 2004-08-02 5 A 0 170 9.59 A 6770 D Incentive Stock Option (right to buy) 6.47 2004-08-12 4 A 0 25000 0 A 2004-08-12 2014-08-12 Common Stock 25000 25000 D Transaction reported on Table I represents Issuer's matching stock contribution pursuant to 401(k) plan. The employee stock option reported in Table II is subject to approval by the Board of Directors and shall vest 25% on the date of the grant, and the balance shall vest in a series of successive equal monthly installments over the next 36 months. Deni M. Zodda 2004-08-13 -----END PRIVACY-ENHANCED MESSAGE-----